Partnering, Acquisitions & Licensing

Partnering

One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances and a flexible and pragmatic approach to licensing and acquisitions. These are fundamental to the company’s continued growth and success.

Our strategy is to develop our business by licensing and acquiring products that we are able to market throughout the Asia Pacific region and to develop partnerships for the global marketing of products developed by Mayne Pharma.

As a partner, Mayne Pharma offers:

• An expanding sales and marketing capability to bring new brands into the Australian market
• A management team and corporate culture committed to partnering
• A proven product development, manufacturing, quality, regulatory and supply chain logistics capability
• A flexible and creative approach to collaborations
• The ability to respond rapidly to opportunities
• A track record of successful partnering (some of our current partners include Warner Chilcott, Pfizer, GSK, Abbott, Meda and Cephalon)

Our Corporate and Business Development Department is a team of business development and alliance management experts who oversee the selection and review of in-licensing and acquisition opportunities, manage the out-licensing process and actively pursue strategic alliances, to build strong relationships that are mutually beneficial to all parties.

 

In-licensing/acquisitions

Mayne Pharma is seeking to rapidly expand its product portfolio in Australia. Our business development activities are focused on prescription, OTC and hospital injectable products that are in late-stage development, currently approved and commercialised outside Australia, or approved in Australia but falling outside the license holder’s business focus. We will consider in-licensing, acquisition, co-promotion, revenue-sharing, and other partnering opportunities. We are focused primarily on oral, topical (including transdermal), injectable dosage form products (NCEs, ICEs or niche/branded generics). Therapeutic categories of primary interest include pain management, infectious disease and cardiology, although we will consider other opportunities outside of these areas.

 

Out-licensing

Mayne Pharma is working to expand its global strategic marketing partnerships for products developed-in house (see Partners, Opportunities and Partially Developed Products). Mayne Pharma products typically incorporate proprietary drug delivery technology offering a therapeutic benefit.  Mayne Pharma aims to provide patent protection for its products and we work closely with our partners to ensure that an effective life-cycle management strategy is in place.

MPG Branded Generic Products (PDF)

 

Contact

If you have a partnering opportunity you would like to discuss with Mayne Pharma please contact Danny Dragovic at danny.dragovic@maynepharma.com
To Top